About: http://data.cimple.eu/news-article/094bc887a91c79858e4f274b673dc03c847da4f213dcc822aec19e56     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

AttributesValues
rdf:type
schema:articleBody
  • A subsidiary of pharmaceutical firm Indivior on Friday admitted to a felony charge as part of a $600 million settlement after the US Justice Department accused it of pushing a treatment for opioid addicts unlawfully. "When a drug manufacturer claims to be part of a solution for opioid addicts, we expect honesty and candor to government officials, as well as to the physicians and patients making important treatment decisions based on those representations," Deputy Assistant Attorney General Michael Granston of the Justice Department's civil division said in a statement. The settlement, which requires approval from a federal judge, comes after a grand jury last year said that Indivior marketed Suboxone Film, an opioid-based drug, as a safe and controllable treatment for opioid and heroin addiction. The grand jury indictment said that Indivior -- until 2014 known as Reckitt Benckiser Group -- sought to boost sales by exaggerating the safety of the drug and connecting patients with doctors who were known to overprescribe it and other opioids, taking advantage of the country's huge opioid addiction crisis. Beginning in 2010, the indictment said, Indivior illegally told health care providers and programs that Suboxone Film, which contains the opioid buprenorphine, was better and safer than similar drugs, when in fact it was not. The aim was to force generic competitors from the market, the indictment said. Reckitt Benckiser Group agreed in July 2019 to pay $1.4 billion -- the largest opioid-related settlement ever -- to resolve its liability in the case. On Friday, Indivior Solutions, a subsidiary of the parent company based in Slough, Britain and Richmond, Virginia, pled guilty to one count of making false statement relating to health care matters. The $600 million fine will be paid along with its parent companies, the Justice Department said. Indivior Chief Executive Officer Mark Crossley said in a statement the incident "does not reflect the values Indivior has strived to demonstrate and uphold during our long history of partnering with health care providers, policymakers, and communities to fight the opioid crisis." cs/mdl
schema:headline
  • Drug firm Indivior to pay US $600 mn over opioid treatment
schema:mentions
schema:author
schema:datePublished
http://data.cimple...sPoliticalLeaning
http://data.cimple...logy#hasSentiment
http://data.cimple...readability_score
Faceted Search & Find service v1.16.115 as of Oct 09 2023


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 5 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software